We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Efficacy and retention times of intravitreal triamcinolone acetonide for macular edema.
- Authors
Akiko Kogure; Kishiko Ohkoshi; Shunsuke Kogure; Tatsuo Yamaguchi; Shoji Kishi
- Abstract
Abstract Purpose  To evaluate the retention of intravitreal triamcinolone acetonide (TA) particles and the efficacy of TA therapy for patients with cystoid macular edema in branch retinal vein occlusion (BRVO) or diabetic macular edema (DME). We monitored the TA particles until absorption from the vitreous cavity was complete. The correlation between the intravitreal retention time of TA and its efficacy was evaluated based on central macular thickness (CMT). Results  The intravitreal TA retention time was a mean 141.8 ± 139.6 days in BRVO patients and 114.5 ± 59.6 days in DME patients. Patient age and retention time were negatively correlated (r = â0.46; P = 0.013). At 6 months posttreatment the mean CMT decreased from 544.1 ± 143.7 to 322.4 ± 131.9 μm in BRVO patients and from 454.5 ± 119.0 to 371.2 ± 209.4 μm in DME patients. Retention time and CMT reduction were positively correlated in BRVO patient (r = 0.56, P = 0.02) but not in DME patients (P = 0.06). Conclusions  Intravitreal TA reduced the CMT in BRVO and DME patients over 6 months. The retention time was longer in younger individuals. The efficacy of the therapy depended on the intravitreal TA retention time observed clinically in BRVO patients. Biomicroscopic examination of intravitreal TA is useful for evaluation of its efficacy.
- Subjects
TRIAMCINOLONE acetonide; RETINAL diseases; RETINAL degeneration; EDEMA; DRUG efficacy
- Publication
Japanese Journal of Ophthalmology, 2008, Vol 52, Issue 2, p122
- ISSN
0021-5155
- Publication type
Article
- DOI
10.1007/s10384-007-0513-7